Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse

Biotechnic and Histochemistry

Volumn 78, Issue 5, 2003, Pages 231-236

  Gruber, Helen E ^a   Rude, R K ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Magnesium deficiency; Osteoclasts; Osteoprotegerin; Ruffled border; Ultrastructure

Indexed keywords

CALCIUM; MAGNESIUM; OSTEOPROTEGERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CELL ACTIVITY; CELL MATURATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; FEMALE; HYPERCALCEMIA; INTESTINE ABSORPTION; MAGNESIUM DEFICIENCY; MICROSCOPY; MINERAL METABOLISM; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; TRABECULAR BONE;

ACID PHOSPHATASE; ANIMALS; CALCIUM; FEMALE; GLYCOPROTEINS; HYPERCALCEMIA; ISOENZYMES; MAGNESIUM DEFICIENCY; MICE; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

ANIMALIA;

EID: 1142287452     PISSN: 10520295     EISSN: None     Source Type: Journal    
DOI: 10.1080/10320290310001630476     Document Type: Article

References (25)

1. Angus RM, Sambrook PN (1988) Dietary intake and bone mineral density. Bone Miner. 4: 265-277.
2. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino ACW, Hay S, Findlay DM (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28: 370-377.
3. Cohen L, Kitzes R (1981) Infrared spectroscopy and magnesium content of bone mineral in osteoporotic women. Isr. J. Med. Sci. 17: 1123-1125.
4. Freudenheim JL, Johnson NE, Smith EL (1986) Relationships between usual nutrient intake and bone-mineral content of women 35-65 years of age: longitudinal and cross-sectional analysis. Am. J. Clin. Nutr. 44: 863-876.
5. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141: 4768-4776.
6. Gruber HE, Marshall GJ, Nolasco LM, Kirchen ME, Rimoin DL (1988) Alkaline and acid phosphatase demonstration in human bone and cartilage: effects of fixation intervals and methacrylate embedments. Stain Technol. 63: 299-306.
7. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140: 4382-4389.
8. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu WR, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157: 435-448.
9. 2D3. J. Bone Miner. Res. 14: 1478-1485.
10. Roodman GD (1996) Advances in bone biology: the osteoclast. Endocr. Rev. 17: 308-332.
11. Rude RK (1996) Magnesium metabolism. In: Bilezikian JP, Raisz L, Rodan G, Markovac J, Eds. Principles of Bone Biology. Academic Press, San Diego, CA. pp. 277-293.
12. Rude RK, Gruber HE, Wei LY, Frausto A, Mills BG (2003) Magnesium deficiency: effect on bone and mineral metabolism in the mouse. Calcif. Tissue Int. 72: 32-41.
13. Rude RK, Kirchen ME, Gruber HE, Meyer MH, Luck JS, Crawford DL (1999) Magnesium deficiency-induced osteoporosis in the rat: uncoupling of bone formation and bone resorption. Magnesium Res. 12: 257-267.
14. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T (2002) Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Anat. Rec. 268: 137-146.
15. Simonet WS, Lacey DL, Dunstan CR, Kelley MCMS, Luthy R, Nguyen HQ, Wooden S, Bennet L, Boone T, Shimamoto G, DeRose M, Eliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
16. Sojka JE, Weaver CM (1995) Magnesium supplementation and osteoporosis. Nutrition Rev. 53: 71-80.
17. Stendig-Lindberg G, Tepper R, Leichter I (1993) Trabecular bone density in a two-year controlled trial of peroral magnesium in osteoporosis. Magnesium Res. 6: 155-163.
18. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289: 1504-1508.
19. Teti A, Marchisio PC, Zallone AZ (1991) Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity. Am. J. Physiol. 261: C1-C7.
20. Tucker K, Kiel DP, Hannan MT, Felson DT (1995) Magnesium intake is associated with bone mineral density in elderly women. J. Bone Miner. Res. 10: S466.
21. Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson RWF, Kiel D (1999) Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am. J. Clin. Nutr. 69: 727-736.
22. Udagawa N, Takashashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA. 87: 7260-7264.
23. Väänäen HK, Horton M (1995) The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J. Cell Sci. 108: 2729-2732.
24. Yano K, Heilbrun LK, Wasnich RD, Hankin JH, Vogel JM (1985) The relationship between diet and bone mineral content of multiple skeletal sites in elderly women living in Hawaii. Am. J. Clin. Nutr. 42: 877-888.
25. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337.